Cryoprecipitated Antihemophilic Factor Market

Cryoprecipitate also known as cryoprecipitated antihemophilic factor is an insoluble material that emerges from a solution after frozen plasma is defrosted between 1?C and 6?C. Rich in specific plasma proteins, such as fibrinogen, cryoprecipitated antihemophilic factor is highly used for the treatment of dysfibrinogenaemia and fibrinogen deficiency, especially in the cases wherein there is clinical bleeding, trauma, or disseminated intravascular coagulation. ?

Cryoprecipitated Antihemophilic Factor Market contains market size and forecasts of Cryoprecipitated Antihemophilic Factor in global, including the following market information:

Global Cryoprecipitated Antihemophilic Factor Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Cryoprecipitated Antihemophilic Factor Market Sales, 2017-2022, 2023-2028, (Kiloton)

Global top five Cryoprecipitated Antihemophilic Factor companies in 2021 (%)

The global Cryoprecipitated Antihemophilic Factor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Recombinant Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cryoprecipitated Antihemophilic Factor include Grifols, Baxter International, CSL Behring, RxList, Haemostatix, Shire US, Bio Products Laboratory, Novo Nordisk and BDI Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Cryoprecipitated Antihemophilic Factor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cryoprecipitated Antihemophilic Factor Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kiloton)

Global Cryoprecipitated Antihemophilic Factor Market Segment Percentages, by Type, 2021 (%)

Recombinant

Plasma Derived

Others

Global Cryoprecipitated Antihemophilic Factor Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kiloton)

Global Cryoprecipitated Antihemophilic Factor Market Segment Percentages, by Application, 2021 (%)

Hypofibrinoginamia

Von Williebrand Disease

Dysfibrinogenamia

Hemophilia A

Uremia

Others

Global Cryoprecipitated Antihemophilic Factor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kiloton)

Global Cryoprecipitated Antihemophilic Factor Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cryoprecipitated Antihemophilic Factor revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Cryoprecipitated Antihemophilic Factor revenues share in global market, 2021 (%)

Key companies Cryoprecipitated Antihemophilic Factor sales in global market, 2017-2022 (Estimated), (Kiloton)

Key companies Cryoprecipitated Antihemophilic Factor sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Grifols

Baxter International

CSL Behring

RxList

Haemostatix

Shire US

Bio Products Laboratory

Novo Nordisk

BDI Pharma

Octapharma